Tag: autosomal dominant polycystic kidney disease

1. Estimated glomerular filtration rate (eGFR) declined less over one year of treatment for patients with later-stage autosomal dominant polycystic kidney disease (ADPKD) taking tolvaptan than those taking placebo. 2. Liver enzyme increases above 3 times the upper limit of normal (ULN) and serious liver-related events occurred more in the...
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Non-publication of large randomized clinical trials: cross sectional analysis Efforts, including the listing of industry affiliations and the listing of trials on clinicaltrials.gov, have been made to improve the transparency...